ARTICLE SUMMARY:
The companies vying for leadership in blood-based colorectal cancer screening seem poised for a particularly eventful year, as data emerges on their tests almost simultaneously with finalization of a CMS NCD that seems likely to secure reimbursement for high-performing assays.
2020 was a breakout year for the liquid biopsy field and liquid biopsy manufacturers are indicating that this year will be even more important for making progress on both clinical evidence and commercialization.